Does Scripps Health Cover Prolia?

What Is Prolia and Why Does Coverage Pathway Matter?

Prolia is a RANK-ligand inhibitor. It works by blocking osteoclast formation, reducing bone resorption, and measurably increasing bone mineral density at the lumbar spine and total hip. The FDA approved denosumab 60 mg in 2010 for postmenopausal women at high fracture risk, and later for men with osteoporosis, bone loss from androgen-deprivation therapy, and bone loss from aromatase-inhibitor therapy in women with breast cancer [1].

Why the Billing Pathway Determines Coverage

Unlike oral bisphosphonates dispensed at a pharmacy, Prolia is a subcutaneous injection administered in a clinical setting every 6 months. That office-based administration means the drug is almost always billed under the medical benefit (CPT code 20610 or J0897 for the drug itself) rather than the pharmacy benefit. This distinction matters enormously for cost-sharing calculations.

Patients with a $10 pharmacy copay may face 20% coinsurance on the medical-benefit side, which on a $1,400 list-price injection equals $280 out-of-pocket per dose without secondary coverage or assistance programs.

Clinical Evidence Driving Coverage Decisions

Insurers anchor coverage criteria to the evidence base. The FREEDOM trial (N=7,808) showed denosumab produced a 68% reduction in new vertebral fractures, a 40% reduction in hip fractures, and a 20% reduction in nonvertebral fractures compared with placebo over 36 months (P<0.001 for vertebral endpoint) [2]. The extension study (FREEDOM Extension, up to 10 years) showed sustained BMD gains with no plateau [3]. These data form the clinical backbone that payers, including Scripps-affiliated plans, use when building coverage criteria.

How Scripps Health Insurance Coverage Works for Prolia

Scripps Health operates as both a provider network and an insurance entity in San Diego County through Scripps Health Plan and affiliated products. Coverage for Prolia runs through several distinct channels depending on which plan a patient holds.

Scripps Health Plan Commercial Products

Scripps Health Plan commercial products (employer-sponsored and individual-market plans offered through the Scripps system) follow California Department of Managed Health Care regulations. Under California law, essential health benefits must cover FDA-approved medications. Prolia, as an FDA-approved drug for postmenopausal osteoporosis, falls within those benefits [4].

Coverage is not automatic. Most Scripps-affiliated commercial plans require:

• A documented DXA T-score of -2.5 or lower (osteoporosis), or a T-score of -1.0 to -2.5 (osteopenia) combined with a FRAX 10-year major osteoporotic fracture probability of 20% or higher, per National Osteoporosis Foundation guidelines [5].
• Prescriber documentation that the patient is at high fracture risk.
• Prior authorization approval before the first injection.
• In many plans, evidence of an adequate bisphosphonate trial (typically alendronate 70 mg weekly for at least 6 months) or documented intolerance/contraindication to bisphosphonates.

Medicare Advantage Plans Administered Through Scripps

Many Scripps Health patients are enrolled in Medicare Advantage (MA) plans that contract with the Scripps network. Prolia given in a Scripps clinic is billed to Medicare Part B under the MA plan, not to Part D. CMS covers denosumab 60 mg under Part B when the drug is administered incident-to a physician visit [6].

Medicare Advantage plans must cover all services that Original Medicare covers, but they may impose additional prior-authorization requirements beyond Original Medicare. In 2023, CMS finalized rules limiting excessive prior-authorization burdens in MA plans, but PA for Prolia remains common [7].

Original Medicare (Parts A and B) at Scripps Facilities

Patients with Original Medicare (not MA) who receive Prolia at a Scripps outpatient clinic are covered under Part B. After meeting the Part B deductible ($240 in 2024), Medicare pays 80% and the patient owes 20% coinsurance. Medigap policies (Plans C, D, F, G, M, N) cover all or part of that 20% [6].

Prior Authorization: What Scripps Providers and Patients Must Submit

Prior authorization is the single most common barrier to Prolia access. Understanding the documentation requirements shortens approval timelines from weeks to days.

Required Clinical Documentation

Most PA requests for Prolia require the following items. Missing even one typically triggers a delay or denial:

• Recent DXA report (within 24 months) with T-scores at spine and hip.
• Prescriber attestation of diagnosis (postmenopausal osteoporosis, male osteoporosis, GIOP, or treatment-related bone loss).
• FRAX score if T-score is in the osteopenia range.
• Documentation of bisphosphonate trial or clinical rationale for bypassing step therapy (esophageal disorders, malabsorption syndromes, chronic kidney disease stage 3b or above where bisphosphonates carry added risk).
• ICD-10 code (M81.0 for age-related osteoporosis without fracture; M80.00 for osteoporosis with pathological fracture; or condition-specific codes for secondary osteoporosis).

Step Therapy and How to Bypass It

Several Scripps-affiliated and commercial plans mandate step therapy before approving Prolia. The most common required step is alendronate (Fosamax) 70 mg weekly. Risedronate and zoledronic acid are accepted step agents on some formularies.

Clinically appropriate step-therapy bypass criteria include:

• GFR <35 mL/min/1.73m² (bisphosphonates accumulate in advanced CKD and carry regulatory caution labels at this threshold) [8].
• Documented history of esophageal stricture, achalasia, or inability to remain upright 30 minutes after oral dosing.
• Prior bisphosphonate use with confirmed fracture progression on therapy.
• Atypical femoral fracture history attributed to bisphosphonate use.

California SB 524 (effective 2018) requires that health plans honor a step-therapy exception when a treating physician documents that the required step agent is clinically contraindicated or previously failed. Providers at Scripps can invoke this statute directly in the PA letter.

Appeal Process If Prolia Is Denied

Roughly 40-60% of initial PA denials for specialty osteoporosis medications are reversed on first-level appeal when a complete clinical record is submitted [9]. A denial is not the end.

Steps to appeal a Prolia denial through a Scripps-affiliated plan:

1. Request the denial letter with the specific clinical criteria the plan used.
2. Submit a Level 1 internal appeal with any missing documentation (DXA, FRAX, CKD labs, GI records).
3. If the Level 1 appeal is denied, request an independent medical review (IMR) through the California Department of Managed Health Care. California mandates IMR decisions within 45 days for standard disputes and within 3 business days for urgent/expedited cases.
4. For Medicare Advantage denials, request a Qualified Independent Contractor (QIC) review at Level 2 of the Medicare appeals process.

Cost of Prolia Without Full Coverage and Assistance Programs

Even with approval, patients may face significant cost-sharing. The average wholesale price of one Prolia injection is approximately $1,390 to $1,450 depending on the source and year [10]. Out-of-pocket exposure depends on coinsurance tier.

Amgen SupportPlus Program

Amgen, the manufacturer of Prolia, offers the Amgen SupportPlus program. Commercially insured patients who qualify may pay as little as $0 per injection for up to 24 months. Eligibility requires:

• Commercial (non-government) insurance.
• Income at or below 500% of the federal poverty level for full subsidy tiers.
• Prescriber enrollment in the Amgen support hub.

Patients on Medicare or Medicaid are not eligible for manufacturer copay cards but may qualify for the Amgen Safety Net Foundation, which provides free drug to uninsured or underinsured patients meeting income thresholds [10].

Medicare Extra Help / Low Income Subsidy

Because Prolia is billed under Part B rather than Part D in most cases, the Low Income Subsidy (LIS/"Extra Help") program does not directly apply. However, patients with both Medicare and Medicaid (dual-eligible) have their Part B coinsurance covered by Medicaid, effectively reducing their Prolia cost to $0 at a Scripps facility [6].

State Pharmaceutical Assistance Programs

California does not currently operate a broad state pharmaceutical assistance program equivalent to programs in New York or Pennsylvania. Patients should confirm current eligibility through the California Department of Health Care Services.

Clinical Criteria: Who Qualifies for Prolia Coverage?

Insurance coverage criteria closely track the FDA-approved indications and the clinical thresholds in the American Association of Clinical Endocrinology (AACE) and Endocrine Society guidelines.

FDA-Approved Indications Covered by Most Plans

The following indications are covered by most Scripps-affiliated plans when documented correctly [1]:

• Postmenopausal women with osteoporosis at high risk of fracture (defined as history of osteoporotic fracture, or multiple risk factors for fracture, or prior bisphosphonate failure).
• Men with osteoporosis at high risk of fracture.
• Men receiving androgen-deprivation therapy (ADT) for non-metastatic prostate cancer who are at high risk of fracture.
• Women receiving aromatase-inhibitor therapy for breast cancer at high risk of fracture.
• Glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture who are initiating or continuing systemic glucocorticoids at a dose of at least 7.5 mg/day of prednisone equivalent for at least 6 months.

AACE/ACE High-Risk Criteria

The 2020 AACE/ACE Clinical Practice Guidelines define "high fracture risk" as any one of the following [11]:

• T-score of -2.5 or below at spine or hip.
• History of fragility fracture of spine or hip.
• T-score between -1.0 and -2.5 with FRAX 10-year major osteoporotic fracture risk of 20% or higher, or 10-year hip fracture risk of 3% or higher.
• Very high risk: T-score of -3.0 or below, multiple fractures, or fracture while on approved osteoporosis therapy.

The AACE guidelines state: "Pharmacological therapy is recommended for postmenopausal women with osteoporosis as defined by DXA T-score of -2.5 or below, or a history of hip or vertebral fracture" [11]. Documenting which AACE risk tier the patient falls into in the PA letter substantially improves approval rates.

Prolia vs. Oral Bisphosphonates: Why Some Patients Need Prolia Specifically

Payers prefer lower-cost first-line agents. Understanding the clinical reasons Prolia is superior for specific patient populations helps providers write stronger PA letters.

Renal Impairment

Bisphosphonates accumulate in bone and kidney tissue. Alendronate, risedronate, and ibandronate are contraindicated or not recommended when creatinine clearance drops below 35 mL/min. Zoledronic acid carries the same restriction. Denosumab has no renal dose adjustment requirement and remains one of the few anti-resorptive agents usable across all stages of CKD [8]. A 2020 systematic review found denosumab produced significant BMD increases in patients with CKD stages 3-5 without worsening renal function [12].

GI Intolerance and Adherence

Oral bisphosphonates require fasting, strict upright posture, and cause upper GI symptoms in a meaningful subset of patients. Adherence to weekly alendronate at 1 year is approximately 40-50% in real-world studies [13]. Prolia's twice-yearly injection dosing, administered in the clinic, removes the adherence variable entirely. That argument belongs explicitly in a PA letter when requesting step-therapy bypass.

Breast and Prostate Cancer Patients

Patients on aromatase inhibitors lose bone at approximately 1-2% per year at the lumbar spine [14]. Denosumab 60 mg every 6 months has been shown to increase lumbar spine BMD by 5.5% over 24 months in this population versus a 1.0% loss in the placebo arm in the ABCSG-18 trial (N=3,425, P<0.001) [15]. This trial is directly relevant when seeking coverage for AI-associated bone loss, and Scripps oncology teams routinely use it in PA submissions.

Prolia Administration at Scripps Facilities: Logistics and Billing Codes

Prolia is administered as a 60 mg subcutaneous injection, typically in the upper arm, thigh, or abdomen. At Scripps outpatient clinics, the visit is billed using:

• J0897: HCPCS code for denosumab 1 mg (one injection = 60 units billed as J0897 x 60).
• 96372: CPT code for therapeutic/prophylactic/diagnostic injection, subcutaneous or intramuscular.
• 99213 or 99214: Office visit E/M code if the visit includes evaluation and management.

Patients should confirm with their Scripps care team whether the injection can be administered as a standalone nursing visit (lower E/M code, lower cost-sharing) versus during a full physician evaluation.

Timing of Injections

Missing or delaying a Prolia injection by more than 4-6 weeks carries clinical risk. Bone turnover markers rebound rapidly after denosumab discontinuation, and multiple vertebral fractures have been reported following abrupt discontinuation [16]. Once a patient starts Prolia, continuity of coverage is not just a convenience issue. Scripps pharmacists and care coordinators typically flag upcoming 6-month intervals for PA renewal to prevent gaps.

Monitoring Requirements That Support Ongoing Coverage

Continued coverage for Prolia past the initial authorization period typically requires documented monitoring. Plans generally require annual DXA (or every 1-2 years) to demonstrate stable or improving BMD. Standard monitoring labs include:

• Serum calcium before each injection (hypocalcemia is a contraindication; correct vitamin D deficiency before dosing) [1].
• Serum 25-hydroxyvitamin D and parathyroid hormone if hypocalcemia risk is elevated.
• Dental evaluation before initiating therapy given the rare risk of medication-related osteonecrosis of the jaw (MRONJ), estimated at <0.1% in osteoporosis dosing per a 2022 meta-analysis [17].

The Endocrine Society 2019 guideline recommends: "All patients receiving pharmacological therapy for osteoporosis should have calcium and vitamin D intake optimized, and BMD should be reassessed by DXA every 1-2 years until stable, then every 2-3 years" [18].

What to Do If Your Scripps Plan Still Denies Prolia Coverage

A final denial from a Scripps-affiliated plan is not a closed door. Patients and providers have several remaining options:

1. External IMR (California DMHC): File at dmhc.ca.gov. The independent reviewer is a physician not affiliated with the plan. California IMR decisions for osteoporosis medications favor the patient in roughly 60% of cases where high fracture risk is documented.
2. Amgen Free Drug Program: Amgen's Safety Net Foundation provides free Prolia to uninsured and underinsured patients. Annual household income must be at or below 600% of the federal poverty level. Apply at amgensupportplus.com.
3. Transition to Zoledronic Acid (if renal function permits): For patients without CKD or GI contraindications, IV zoledronic acid 5 mg annually is covered under Part B with fewer PA hurdles and has comparable fracture-reduction efficacy to denosumab in indirect network meta-analyses [19].
4. Contact Scripps Patient Financial Counseling: Scripps Health operates financial counseling services at each major campus. These counselors can identify plan-specific assistance, charity care options, and manufacturer programs the prescribing team may not be aware of.